Global Pulse

分类： health

  • Researchers launch study on Ebola treatments as Congo outbreak worsens

    Researchers launch study on Ebola treatments as Congo outbreak worsens

    A long-awaited clinical study to evaluate two potential Ebola treatments officially got underway Thursday in the Democratic Republic of the Congo, with the World Health Organization (WHO) confirming the enrollment of the trial’s first participant. The launch comes as a still-expanding outbreak of the rare Bundibugyo strain of Ebola continues to devastate eastern regions of the country, leaving global and local health officials scrambling for targeted solutions.

    Unlike the more widespread Zaire strain of Ebola, the Bundibugyo variant has no approved, specific vaccines or treatment protocols available for use today. As of Thursday, WHO Director-General Tedros Adhanom Ghebreyesus reported that the outbreak has already infected more than 1,400 people and claimed 438 lives. While basic supportive care – when administered early in the course of infection – can improve patient outcomes, with more than 200 people having recovered so far, public health leaders emphasize that more effective interventions are desperately needed to curb the outbreak’s growth.

    In his official statement marking the trial’s launch, Tedros framed the research initiative as a critical source of optimism for affected communities, noting that it “offers real hope that we can deliver concrete results for – and with – the communities at the heart of the outbreak.”

    The trial will compare the survival outcomes of patients receiving two experimental antiviral therapies against current standard care. The first candidate, remdesivir, is a broad-spectrum antiviral already approved for the treatment of COVID-19, manufactured by Gilead Sciences. Preliminary laboratory testing has already yielded early signs that the drug may be active against the Bundibugyo strain now spreading in Congo. The second candidate, MBP134, is an experimental monoclonal antibody treatment developed by Mapp Biopharmaceutical, engineered specifically to bind to and neutralize multiple strains of Ebola, including Bundibugyo.

    Dr. Vasee Moorthy, a research adviser at the WHO, explained the trial’s methodology: all enrolled participants will receive the current best available standard care, then be randomly assigned to one of four groups: remdesivir alone, MBP134 alone, a combination of both drugs, or no additional experimental treatment. Researchers will track patient survival rates for 28 days after the initiation of treatment.

    Moorthy cautioned that clear, definitive results will not come quickly. The study may require several months of data collection and up to 1,000 total participants to confirm whether either treatment improves survival. He added, however, that if one of the candidates proves to be highly effective, researchers could reach a conclusion sooner with a smaller patient pool.

    At present, the trial is only open to patients at a single Ebola treatment center located in Congo’s Ituri province, a region that has been severely impacted by ongoing armed violence. Targeted attacks against healthcare workers responding to the outbreak have made operating in much of the region unsafe, so officials plan to expand the trial to additional treatment sites only once security conditions improve to allow safe operations.

    According to Moorthy, pharmaceutical developers and government partners have already donated a sufficient supply of both experimental drugs to complete the trial. Gilead has donated its supply of remdesivir, while the U.S. government – which funded MBP134 development and owns the trial doses – has contributed the supply of the antibody treatment. If either candidate is found to be effective, stakeholders will immediately move to expand access to the treatment for all patients affected by the outbreak, not just those enrolled in the clinical study.

    The WHO-backed trial is the product of a global collaborative effort, bringing together Congo’s national biomedical research institute INRB, the University of Oxford in the United Kingdom, the Institute of Tropical Medicine in Antwerp, and multiple other international public health organizations.

    This reporting is part of coverage from The Associated Press Health and Science Department, which receives grant support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP maintains full editorial control over all published content.

  • Canadian boy, 11, dies of rabies after waking to bat on his face

    Canadian boy, 11, dies of rabies after waking to bat on his face

    An 11-year-old unvaccinated Canadian child has succumbed to a rabies infection, a fatal outcome that public health experts say could have been prevented, following an unexpected encounter with a bat at a family cottage in 2024. The tragic case, detailed in a new report published Monday in the *Canadian Medical Association Journal*, has reignited conversations about the dangers of underpreparing for wildlife encounters and gaps in public awareness around rabies exposure protocols.

    The boy, whose identity has not been released to protect his family’s privacy, was staying at a rural Ontario cottage when he was woken in the night by a bat clinging to his nose and mouth. He quickly swatted the animal away, and his father captured it in a container before releasing it back into the wild outside the cottage.

    Because the child had no visible bite marks or open wounds, and the bat did not display any obvious unusual or erratic behavior, his parents opted not to seek immediate medical care. That decision would prove devastating. Nineteen days after the encounter, the boy first developed unexplained numbness and swelling across his face, prompting his family to seek emergency medical attention.

    Over the next several days, medical providers worked to pinpoint the cause of his worsening symptoms. Initially, an urgent care clinic misdiagnosed his condition as Bell’s palsy, a temporary facial muscle paralysis, and sent him home with antiviral medication typically used to treat herpes virus infections. When his symptoms did not improve, he was taken to a local hospital, where clinicians first suspected herpes gingivostomatitis, a common viral infection affecting the mouth and gums. The following day, he returned after the entire right side of his face became paralyzed.

    While waiting for a hospital bed, the boy’s condition deteriorated sharply: he developed a 39-degree Celsius fever, struggled to swallow, experienced confusion and visual hallucinations. He was quickly intubated and transferred to a pediatric intensive care unit, where specialists from the University of Manitoba’s Department of Pediatrics and Child Health raised an urgent red flag: the symptoms aligned almost perfectly with rabies infection. Subsequent testing confirmed their suspicion, and the Canadian Food Inspection Agency later identified the strain as a bat-specific rabies virus variant. The boy died 17 days after being admitted to intensive care. Medical records show he had no pre-existing allergies, no known exposure to sick contacts, no recent tick bites, and had not traveled outside of Canada in the months before his illness.

    Rabies infections in humans are extremely rare in Canada. According to data from the Canadian Veterinary Medical Association, only 28 people have died from rabies in the country since 1924. The organization credits this decades-long low fatality rate to widespread, sustained animal rabies vaccination programs across the country, warning that any interruption to these programs would almost certainly lead to a resurgence of preventable human cases.

    Public health guidelines universally recommend that any direct physical contact between a human and a bat warrants immediate post-exposure rabies prophylaxis, a timely medical intervention that prevents the virus from taking hold in the body. Medical experts have repeatedly emphasized that rabies is almost universally fatal once clinical symptoms develop, making immediate preventive care after exposure critical to survival.

  • Lethal Weapon actor Danny Glover reveals Alzheimer’s diagnosis

    Lethal Weapon actor Danny Glover reveals Alzheimer’s diagnosis

    Veteran American actor and activist Danny Glover has opened up about his multi-year journey living with Alzheimer’s disease, sharing his diagnosis publicly in a new interview to challenge widespread stigma surrounding the neurodegenerative condition. The 79-year-old performer, best known for his decades-long career on screen and his lifelong advocacy for social justice, told NBC in an interview that aired Wednesday that he received his diagnosis shortly after being awarded an honorary Oscar in 2022.

    Since receiving that diagnosis, Glover acknowledged that his speech, movement and memory have gradually slowed, but he emphasized that he continues to maintain an active lifestyle. “I can live with it in a sense,” Glover shared in the pre-taped conversation with former NBC Nightly News anchor Lester Holt, which aired on *The Today Show*. “I’m sure as it advances, things are going to be different and changing.”

    A four-time Emmy Award winner with over 170 acting credits spanning more than five decades, Glover rose to global fame in the 1980s for his portrayal of Detective Roger Murtaugh opposite Mel Gibson in the blockbuster *Lethal Weapon* franchise. He also earned widespread critical acclaim for his roles in iconic films including 1984’s *Places in the Heart* and 1985’s *The Color Purple*. Beyond his acting work, Glover founded a production company focused on developing and financing films centered on progressive political and social themes, a reflection of his longstanding commitment to social justice causes.

    Glover and his family made the deliberate choice to speak out about his diagnosis to shift harmful public narratives around Alzheimer’s, a disease that currently impacts an estimated 7 million Americans aged 65 and older. For Glover’s daughter Mandisa Glover, the decision to let her father control his own story could not wait. “I think it’s really important for him to have control of his own narrative, of his own life story,” she said. “That’s really important. And the time is now. What better time but now for him to speak for himself?”

    Alzheimer’s, the most common form of dementia, gradually impairs memory, cognitive function and behavior, with symptoms typically worsening over time until they interfere with basic daily activities. Data from the U.S. Alzheimer’s Association highlights a stark racial disparity in diagnosis rates: older Black Americans like Glover are twice as likely to develop Alzheimer’s or another form of dementia as older white Americans, though researchers have not yet pinpointed the root causes of this gap. Reflecting on his legacy and the role of creativity in navigating life’s challenges, Glover noted: “We have challenges in the world. I think art becomes a reframe, a way of looking at that, you know?”

  • Hospitals in Europe are gearing up for the next heat wave armed with lessons from this one

    Hospitals in Europe are gearing up for the next heat wave armed with lessons from this one

    When a historic, temperature-shattering heat wave swept across Western Europe earlier this summer, it pushed French healthcare facilities to their breaking point — exposing critical gaps in preparedness that medical providers and government leaders are now rushing to fix as climate change makes extreme summer heat a permanent new public health reality. \n\nAt Paris-Saclay Hospital, located just outside the French capital, emergency medical teams faced a staggering, unanticipated shortage of one life-saving resource last week: large volumes of ice. With patients flooding in suffering from dangerous overheating, medics needed to immediately lower core body temperatures via cold water immersion to prevent fatal heat complications. But the facility had no on-site ice machine, forcing staff to scramble for last-minute solutions. A local fast-food chain stepped in to donate its entire stock of ice, while care teams purchased additional supplies from nearby grocery stores. Today, the hospital has placed an order for its own dedicated ice machine, a piece of equipment the emergency department now counts as a critical priority for the next heat event. \n\nThe historic heat wave, which initially battered France, the United Kingdom and neighboring nations before shifting eastward across the European continent, left a growing death toll in its wake. Now, as forecasters warn another heat surge could hit France as early as next week, healthcare leaders say the chaotic, exhausting ordeal of the past week has made clear that heat wave response is the new normal for the medical sector — analogous to the annual preparation for winter flu season. \n\n“We thought we were ready. We were not actually,” shared Cédric Lussiez, director of the Paris-Saclay public hospital system, in an interview. For seven straight days, the hospital operated around the clock, improvising new protocols and solutions on the fly to match the surging demand for heat-related care. “We already learned some lessons,” Lussiez added. \n\nAcross France, national efforts to close preparedness gaps are accelerating rapidly. Shortly after the peak of last week’s record heat, French Prime Minister Sébastien Lecornu announced a 100-million-euro ($114-million) investment starting this summer to install cooling systems in hospitals and upgrade heat-resilient infrastructure across healthcare wards. During a crisis planning meeting Monday, Lecornu confirmed the national government is purchasing 30,000 new air conditioning units for health facilities, with the first shipments set to arrive by the end of this week. “It’s an absolute priority for us that, if the heat wave returns, the hospital situation be a lot less strained,” he said. \n\nGlobal health officials have underscored that the 2026 heat wave is not an isolated anomaly, but a preview of what summers will look like as the planet warms. The World Health Organization labeled the event a “dress rehearsal” for future, more severe summer heat events this week, noting that Europe is warming more than twice as fast as the global average. “Heat waves are no longer one-off freak events,” the organization stated. “Every summer we fail to prepare for them is a summer we pay for in lives.” \n\nFor frontline medical teams at Paris-Saclay, the human cost of that unpreparedness was on full display. Dr. Nicolas Gonzales, head of the hospital’s emergency department, reported that heat-related patient arrivals surged starting June 20, with a seven-day continuous wave of critical cases that felt like “a big mountain” bearing down on staff. “In winter, we know we’ll have influenza epidemics and probably COVID as well. And now, in the summer, we’re going to have the climate crisis,” he said. \n\nThe first heat-related critical case Gonzales treated was a 50-year-old man who slipped suddenly into a coma at home with a core temperature of 40 degrees Celsius (104 Fahrenheit), going from seemingly healthy to unconscious in minutes. After that first case, a flood of patients followed: cases of heat-induced heart attacks, severe dehydration, kidney failure, and other life-threatening conditions across every age group, from young children to isolated elderly residents. “Heat is a physical assault. It is a physical assault on the body,” Gonzales explained. “And when the body can no longer adapt — or, unfortunately, is no longer able to fight off that assault — you don’t feel it coming, and the heart can stop beating.” \n\nWhile the main Paris-Saclay Hospital building is new and equipped with full central air conditioning, three older facilities in Lussiez’s hospital network lacked adequate cooling systems, and were pushed to the breaking point during the heat peak. Temperatures on the top, most sun-exposed floor of one psychiatric unit hit 33 degrees Celsius (91 Fahrenheit), while medical teams had to improvise cooling for temperature-sensitive medications using electric fans and loose ice blocks. Student nurses were reassigned to help with frequent patient hydration checks to prevent worsening heat complications. \n\nIn response to the gaps exposed by the heat wave, Lussiez’s team is already rolling out urgent upgrades: the psychiatric unit will get a dedicated cool patient room on each floor, the elderly care department will be relocated to the cooled main hospital building, and a host of other renovations are moving forward at an accelerated pace. “We’ll be in a better situation next week than we were last week,” Lussiez said, a small note of cautious optimism as the region braces for the next potential heat surge.

  • Restoring dignity one haircut at a time in Kenya’s largest mental health hospital

    Restoring dignity one haircut at a time in Kenya’s largest mental health hospital

    At Mathari National Teaching and Referral Hospital, Kenya’s largest facility for specialized mental health care, a unique, community-led therapy program is transforming the recovery journey for male patients: monthly free personal grooming sessions delivered by volunteer barbers. As soon as barbers lay out their clippers, scissors and shaving supplies, a palpable wave of excitement moves through the waiting group of patients. One by one, men take their seat in the temporary barber chair, eager to walk away with a fresh cut and clean shave that many have not had in months.

    Healthcare providers at the facility explain that targeted self-care interventions like this fill a critical gap in standard mental health treatment. A common, widely overlooked symptom of many mental health conditions—particularly depression, which is one of the most prevalent mental health disorders in Kenya—is a gradual loss of motivation to maintain personal hygiene and physical appearance. For patients struggling with severe mental illness, this neglect can quickly spiral into lower self-worth, deeper social isolation, and slower progress toward recovery.

    Kenya’s mental health care system still faces major gaps in data and infrastructure, with limited national tracking of mental illness prevalence. The most recent official government policy framework, released in the 2015 National Mental Health Policy, estimates that 25% of all outpatient care attendees and 40% of inpatient admissions across Kenyan health facilities live with a diagnosable mental health condition. Mental health practitioners note that mood disorders like depression and anxiety top the list of most commonly diagnosed conditions, while substance use disorders remain an especially persistent and widespread challenge among male patients.

    The initiative comes as June marks global Men’s Mental Health Awareness Month, a moment that local health workers are leveraging to encourage a cultural shift in how Kenyan men address mental health struggles. Francis Kabugua, a senior nursing officer at Mathari Hospital, stresses that harmful cultural expectations of emotional stoicism often push men to cope with distress through harmful coping mechanisms rather than open discussion. “Many men with progressive depressive disorders start to withdraw from their families, step back from their responsibilities, and isolate themselves entirely,” Kabugua explained. Too often, instead of seeking professional support, they turn to alcohol and drugs to numb their symptoms, worsening their condition over time.

    The free grooming program is run by Uniquely Gifted, a community-based organization founded by Sheila Lugaliki, who drew on her own personal experience receiving inpatient psychiatric care to launch the monthly initiative. “I saw firsthand what it feels like to be hospitalized for months without anyone helping you care for your appearance, and how that makes you feel invisible and neglected,” Lugaliki said. She designed the program not just as a practical service, but as a gesture of human connection: the simple act of a haircut is intended to restore patients’ sense of dignity, rebuild their confidence, and remind them that they are seen and valued members of the community. “When someone has been admitted for half a year and no one has trimmed their hair, their outward appearance doesn’t just reflect neglect—it deepens the negative feelings they already have about themselves,” she added.

    Titus Enko, a psychiatric nurse at Mathari Hospital, echoes this perspective, noting that personal care is often sidelined in treatment plans that prioritize medication and traditional talk therapy. “We focus so much on clinical interventions that we forget the small, tangible acts of care that signal recovery. When a patient starts caring about how they look, that’s a clear sign they are starting to feel better about themselves,” Enko explained. “Personal grooming builds self-esteem, and that boost in self-worth directly supports long-term recovery and overall well-being.”

    By the end of the latest grooming session, as barbers finished trimming beards and cleaning up necks, one patient summarized the impact of the program in one simple, powerful word: he said he felt “alive.”

  • DR Congo bans mass gatherings in the capital to prevent spread of Ebola

    DR Congo bans mass gatherings in the capital to prevent spread of Ebola

    The Democratic Republic of Congo (DRC) has implemented a sweeping ban on mass gatherings in its capital city Kinshasa and four neighboring provinces, a public health measure aimed at stopping the fast-spreading Ebola outbreak from reaching one of Africa’s most densely populated urban centers, the country’s interior minister has announced.

    As of Saturday, when the new directive was issued, the deadly viral outbreak has been officially confirmed in three eastern DRC provinces — Ituri, North Kivu, and South Kivu — located roughly 1,800 kilometers (1,100 miles) from Kinshasa, a megacity home to 18 million residents. The ban extends beyond Kinshasa to three additional eastern provinces that share borders with the affected regions: Tshopo, Haut-Uele, and Bas-Uele. Mass gathering restrictions have already been in place in the three core affected provinces for weeks, with Ituri bearing the overwhelming brunt of the crisis, accounting for more than 90% of all recorded infections.

    On the day the new ban was announced, health authorities recorded a single-day jump of 47 new confirmed cases, pushing the national total of infections to 1,274, with the confirmed death toll rising to 360. Neighboring Uganda has also detected cross-border spread of the virus, with 20 confirmed infections and two recorded deaths, according to the World Health Organization (WHO).

    This outbreak is unusual in that it is caused by the Bundibugyo strain of Ebola, for which no widely approved vaccine currently exists. Public health bodies including Africa’s Centres for Disease Control and Prevention (Africa CDC) and U.S. health agencies have warned that the outbreak has the potential to become one of the largest on record, because transmission went undetected for several weeks before the virus was formally identified. Ongoing armed conflict in eastern DRC, where the M23 rebel group controls large swathes of North and South Kivu, has further complicated outbreak response efforts, the WHO added.

    The implementation of the ban has already sparked political controversy, with major opposition figures arguing the restriction is a deliberate attempt to block a planned opposition protest scheduled for July 8. The demonstration is organized by the C64 coalition, an opposition alliance opposing a proposed new law that critics warn would allow current President Felix Tshisekedi to extend his time in office beyond the constitutional two-term limit.

    Opposition leaders point out that no Ebola cases have yet been confirmed in Kinshasa, making the public health justification for the ban unconvincing. Prince Epenge, spokesperson for the opposition Lamuka coalition, called the government’s decision an overtly political move. “It is not legitimate. We cannot accept this decision,” Epenge told the BBC Monday. Rodrigue Ramazani, secretary-general of the opposition Envol party, echoed those criticisms, saying the directive “reeks of a political manoeuvre rather than a public health measure,” and urged planned protesters to defy the ban and attend the march. As of Tuesday, the Congolese government has not issued any public response to the opposition’s allegations.

    While Kinshasa has no confirmed local cases to date, the city has been linked to a recent exported case: a doctor who worked at an Ebola treatment center in the outbreak’s epicenter passed through Kinshasa while traveling home to France, where he later tested positive for the virus. Shortly after the doctor’s positive test was announced, the DRC government implemented a 21-day quarantine mandate for all travelers moving from affected provinces to other parts of the country.

  • To beat China in the lab, America’s edge is trust not speed

    To beat China in the lab, America’s edge is trust not speed

    As geopolitical competition increasingly extends into the life sciences sector, the United States faces growing anxiety over China’s rapid ascent in global clinical drug research. While this concern is grounded in tangible data, framing reform of U.S. clinical trial systems as a zero-sum race risks overlooking a far more impactful goal: building a faster, safer, globally trusted model for medical innovation that benefits patients worldwide.

    At the center of U.S. reform efforts is a new pilot program launched by the U.S. Food and Drug Administration (FDA), part of a broader initiative led by the Department of Health and Human Services. The program is designed to cut red tape for early-stage clinical trials, with projections that it could shorten overall drug development timelines by 6 to 12 months. This move comes in response to a clear, ongoing industry shift: a growing share of early-stage drug research has relocated outside U.S. borders, drawn to destinations ranging from China to Australia by lower operational costs, streamlined regulatory approval processes, targeted tax incentives and more efficient clinical trial networks.

    The data behind U.S. policymakers’ concerns is stark. Federal officials confirm that China now conducts more clinical drug trials than the United States, and one 2024 estimate places China’s share of all global trials at 39 percent. This shift is far from trivial: early-stage trials are not just routine technical procedures, they are the foundational gateway to global biomedical innovation. The geographic location of these trials shapes which patient populations gain early access to cutting-edge therapies, which academic and medical institutions build specialized research expertise, where billions in global life sciences investment flows, and which nations’ regulatory frameworks ultimately set the global standard for drug development.

    Despite this shifting landscape, the central question facing U.S. leaders is not whether the country can “outcompete” China on trial volume alone. Instead, it is whether the U.S. can restructure its system to be fast enough to retain and attract global research investment, rigorous enough to protect trial participants, and transparent enough to produce clinical evidence that the entire world can rely on.

    The FDA’s proposed regulatory reforms move toward this goal. Under the new framework, the agency will provide pharmaceutical companies with earlier clarity on manufacturing requirements, dose selection and approval pathways, and will offer rolling review of some applications, allowing sponsors to submit materials incrementally rather than waiting to compile a full complete dossier before review begins. The FDA has also reaffirmed a new flexible approach: in select cases, a single high-quality late-stage trial, supported by robust confirmatory evidence, will be sufficient to support drug approval, replacing the longstanding requirement for two separate positive late-stage trials.

    Other federal agencies are joining the push for reform. The National Institutes of Health is set to explore innovative trial designs, integrate artificial intelligence and real-world patient data into research processes, and streamline the slow, fragmented ethics review process. Federal health technology officials are also working to break down data silos, exploring how interoperable electronic health record systems can connect more diverse patient populations to research studies.

    These steps are rooted in a clear diagnosis of U.S. system weaknesses. The American regulatory framework is not slow because regulators oppose innovation. Rather, friction accumulates across a series of disconnected stages: trial activation, contracting, ethics review, site selection, patient recruitment, data collection and communication between sponsors and regulators all operate as separate, uncoordinated layers. While each step was designed to serve a valid purpose, their cumulative effect creates costly delays that drive research activity overseas.

    Yet the reform effort carries a key risk: if speed becomes the only overriding goal, the U.S. could trade its greatest advantage for marginal gains. If faster trials come at the cost of thinner clinical evidence, weaker patient oversight or pressure to rush enrollment to meet arbitrary timelines, the U.S. will not strengthen its global position—it will erode public trust that takes decades to build, and is far harder to recover than a compressed regulatory timeline.

    When assessing China’s rise in clinical research, nuance is critical. China’s growth is not solely the result of subsidies and loose regulation. It reflects decades of deliberate, strategic investment: building dense, coordinated hospital research networks, leveraging its large diverse patient population, cultivating a growing pool of top scientific talent, and aligning industrial policy with public health goals to drive research growth. The U.S. would benefit from studying these strengths honestly rather than relying on caricature; learning from a competitor is not surrender, it is a mark of strategic maturity.

    At the same time, the U.S.’s enduring core advantage has never been primarily speed—it is credibility. FDA approval decisions carry global influence precisely because, for all its imperfections, the agency is widely viewed as methodologically rigorous and comparatively transparent. Instead of copying other nations’ models, the U.S. should anchor its competitive strategy in trust, building a reformed system that prioritizes both speed and credibility.

    One actionable step to achieve this is the creation of a national network of pre-certified “trial-ready” research sites. Rather than treating every study as a one-off project requiring new contracting, ethics review and data standardization from scratch, the government could certify standing research networks that already have master contracts, pre-agreed data standards, robust privacy safeguards, community engagement frameworks and shared centralized ethics review. Sponsors could connect to these networks far faster, and patients and providers would have clear visibility into which sites meet consistent quality benchmarks.

    A second key reform is expanding access to trials beyond major urban elite academic centers, reducing geographic barriers to participation. When patients must travel repeatedly to specialized research centers for trial visits, enrollment remains slow and unequal, excluding large swathes of diverse patient populations. A more practical, accessible model would integrate more trial activities into routine patient care, supported by interoperable electronic health records and strengthened local research networks. This would shift clinical trials from rare, exclusionary events to a normal, accessible part of healthcare for more patients.

    Policymakers also need to distinguish between two distinct forms of speed. Regulatory speed refers to shorter approval queues and clearer, earlier guidance for sponsors—this primarily benefits pharmaceutical companies by cutting development timelines and costs. Evidence speed, by contrast, refers to generating reliable clinical evidence faster through smarter trial designs, improved outcome measures, interoperable data systems, and earlier detection of treatment benefits and harms—this primarily benefits patients. A meaningful, durable reform agenda requires prioritizing both.

    For the broader Asia-Pacific region, the stakes of this reform extend far beyond the U.S.-China bilateral competition. If the U.S. succeeds in pulling large volumes of trials back to domestic sites, regional research centers across Asia could face heightened competition for global investment. But a far better outcome is within reach: a global clinical research ecosystem that is more distributed, interoperable across trusted regulatory jurisdictions, rather than splitting into rival geopolitical blocs. Regulators can compete on quality and efficiency while cooperating on core shared priorities: data integrity, patient protection and universal transparency.

    This collaborative model would benefit all nations: China has a clear stake in building global trust in its research output, the U.S. benefits from learning from efficient systems abroad, and patients everywhere gain faster access to therapies that have been rigorously proven safe and effective, rather than just heavily marketed.

    By this standard, the FDA’s new pilot initiative should be judged against three core tests. First, does it cut unnecessary bureaucracy without lowering standards for clinical evidence? Second, does it expand access to trial participation beyond elite academic centers and large urban hospitals? Third, does it produce transparent, reproducible evidence that other nations can examine, verify and trust?

    If the reforms pass these tests, the U.S. will do more than recapture market share in global clinical trial volume. It will redefine what global leadership in biomedical innovation actually means. In an era of intensifying great power competition, the most successful nation will not be the one that turns scientific research into another geopolitical battlefield. It will be the one that proves speed and public trust can advance together, for the benefit of patients across the world.

    This analysis comes from Y. Tony Yang, an endowed professor at George Washington University in Washington, D.C.

  • Europe’s record heat has overwhelmed Paris mortuaries and left families in distress

    Europe’s record heat has overwhelmed Paris mortuaries and left families in distress

    PARIS (AP) — For mortuary owner Zouhaeir Hertelli, business has taken an unthinkable turn amid Europe’s record-shattering 2022 heat wave: every few minutes, his phone buzzes with a desperate question from funeral directors and grieving families alike: do you have any cold storage space left for another body?

    With all 32 spots in his refrigerated mortuary already occupied, Hertelli has been forced to turn away hundreds of families, repeating the devastating word “No” again and again. “We’re facing a really catastrophic situation,” he told reporters. “I’m getting hundreds of calls.”

    As the blistering heat dome drifted eastward across Europe over the weekend, leaving a trail of fatalities in its wake, France has begun the grim work of counting the human cost of the extreme temperatures that first settled over the country in mid-June.

    Full official mortality counts will take weeks or months to compile, as public health teams cross-reference death certificates and verify heat as a contributing cause. But even the earliest data makes clear the unprecedented toll of this unrelenting heat event, which has hit older and isolated populations particularly hard.

    France’s national public health agency released its first preliminary assessment of the crisis, confirming a dramatic spike in deaths during the heat wave’s peak last week. Temperatures soared above 40 degrees Celsius (104 degrees Fahrenheit) across most of the country, and record-breaking overnight highs left vulnerable bodies with no chance to cool down and recover — a deadly one-two punch that overwhelmed natural defenses.

    On the nation’s all-time hottest day, which broke a record set just 24 hours earlier, more than 1,200 deaths were recorded across France. That number climbed to more than 1,400 the following day, and stayed at that elevated level on the third day of peak heat. For comparison, the average daily death toll in April and May 2022, before the heat wave arrived, ranged between 900 and 1,000.

    The agency estimates that at least 1,000 excess deaths occurred over just those three days, but warns the final toll will be higher. Many deaths occurred in private homes and elderly care facilities, where death registrations are often processed manually rather than electronically, leading to delays in official counting. “Mortality will as a consequence be higher than these first figures,” the agency stated.

    Eighty-five percent of the deaths registered so far from the three-day peak are people aged 65 and older, and deaths at home have jumped by roughly 40% compared to pre-heat wave levels, with the Paris region seeing the sharpest increase.

    Hertelli and other funeral industry professionals across the capital report that all municipal and private mortuary cold storage filled within days of the heat peak. Paris City Hall has responded by installing two temporary cold storage units with 20 spots each at municipal mortuaries, and local hospitals have made an additional 50 spaces available.

    Even with the extra capacity, the shortage remains acute. Hertelli says funeral directors he has spoken with are transporting bodies as far as Chartres, 50 miles southwest of Paris, to find available storage. He has submitted a request to local authorities for permission to park temporary refrigerated shipping containers outside his mortuary, located near Paris Orly Airport, but has not yet received approval. “Families are suffering,” he said. “We have no solution to offer them, because the funeral homes are full. So we are deeply affected, we have empathy for them, but there’s nothing we can offer. We are really facing a problem, a big problem.”

    This heat wave has already surpassed the 2003 European heat event that killed an estimated 15,000 people in France and sparked a national reckoning over the care of vulnerable elderly populations. A 2021 heat wave also killed more than 5,700 people across the country. Many funeral and public health professionals worry that the hard-won lessons of past heat crises have been forgotten as record heat becomes more common.

    Véronique Bertrand, a funeral director based in Paris, notes that most of the recent fatalities she has handled were isolated seniors who lived alone at home. “Given the circumstances in which they were found, there can be no other conclusion than that these were deaths caused by the heat,” she said.

    Bertrand called for a renewal of the community solidarity that emerged after the 2003 tragedy, when neighbors began checking in on isolated older residents to ensure they were staying hydrated and cool. “I think people absolutely need to wake up, that solidarity needs to come back, that what happened in 2003 led to a movement in that direction, with people thinking about their neighbors, of those around them who live alone and perhaps checking from time to time that they’re drinking water and are being looked after,” she said. “With the passing years, we’ve perhaps forgotten that it could happen again and that things would even perhaps be worse.”

  • China-Zimbabwe health partnership delivers new hope to patients

    China-Zimbabwe health partnership delivers new hope to patients

    Across Zimbabwe, thousands of people living with chronic pain, life-threatening acute conditions, and treatment-resistant illnesses are finding new hope through a decades-long health partnership between China and Zimbabwe, centered on expanding access to both traditional Chinese medicine (TCM) and cutting-edge modern medical technologies.

    At the Zimbabwe-China Traditional Chinese Medicine and Acupuncture Center based at Harare’s Parirenyatwa Group of Hospitals, the nation’s top public referral institution, the 10-member 23rd Chinese medical team has built a reputation for life-saving care and transformative treatment. Led by Ma Zheng, a public health specialist from China’s Hunan Provincial Center for Disease Control and Prevention, the team draws on cross-disciplinary expertise from leading Hunan hospitals to treat an average of 30 patients daily, combining TCM practices with modern critical care techniques.

    Stories of dramatic recoveries have spread far beyond Harare’s city limits, drawing patients from hundreds of kilometers across all 10 of Zimbabwe’s provinces, many traveling for more than six hours to access care the center provides. One of the team’s most notable achievements involved rescuing an elderly HIV-positive patient who had developed multiple organ failure stemming from acute heart failure and cardiogenic shock. Local clinicians had been unable to secure venous access after the patient’s peripheral veins collapsed from widespread swelling, but coordinated multidisciplinary emergency intervention from the Chinese team stabilized the patient and pulled him back from the brink of death.

    In another high-stakes case, the team rapidly treated a patient with an acute ischemic stroke within the critical 4.5-hour window that determines long-term outcomes, preventing permanent disability and adding another success story to the growing list of results that have built public trust in Chinese medical expertise among Zimbabweans.

    For patients living with chronic pain that has resisted conventional Zimbabwean healthcare treatments, TCM practices including acupuncture, cupping, moxibustion, massage, and herbal medicine have delivered life-changing relief. Revayi Roselinah Chaitezvi, a Chitungwiza resident who lived with disabling back pain for five years, saw her symptoms subside dramatically after just three acupuncture sessions. For 27-year-old Jomarie Nhari, persistent shoulder pain and muscle strain that failed to respond to expensive conventional physiotherapy also improved dramatically after acupuncture, exceeding all her expectations. Sixty-one-year-old Ivy Gundam, who lives with high blood pressure and chronic knee pain, now says acupuncture has let her regain control of her daily life after years of being limited by discomfort.

    Beyond direct patient care, the partnership is driving long-term progress for Zimbabwe’s entire healthcare system. The Chinese team has introduced advanced neuromodulation technologies—including deep brain stimulation and spinal cord stimulation—for the first time in the country, allowing local clinicians to treat Parkinson’s disease, severe neuralgia, and spinal cord injuries that once required patients to travel abroad for costly care. The team also plans to roll out affordable, easy-to-use rapid multiplex detection testing that can screen for HIV, syphilis, and hepatitis B in a single test, a tool ideal for grassroots community outreach. Regular training programs for local doctors and nurses are also building local capacity to diagnose and manage infectious diseases, creating sustainable skills that extend beyond the team’s deployment.

    The work of the medical team has also inspired a new generation of Zimbabwean healthcare workers to carry TCM practice forward across the country. Charlotte Muziri, a former Miss Zimbabwe Queen and University of Zimbabwe graduate, first connected with the team when her father had a stroke in 2017, and the successful treatment restored hope to her entire family. Today, she volunteers as a trainee at the center and plans to pursue advanced medical studies in China. Munashe Mboneka, one of Zimbabwe’s first locally trained TCM practitioners, completed specialized training in Hunan province in 2022 and now works full-time at the center, where patient demand consistently outstrips available capacity. “The Chinese doctors have become a beacon of hope for Zimbabweans who had exhausted other treatment options,” Mboneka said.

    In addition to fixed care at the Harare center, the team regularly hosts mobile outreach camps across remote rural communities, providing free consultations, acupuncture treatment, disease screening, and health education to thousands of people who would otherwise lack access to these services.

    This current chapter of collaboration builds on a health partnership that stretches back more than 40 years. China first sent medical teams to Zimbabwe in 1985, and has since supported the construction of major public healthcare facilities including Chinhoyi Provincial Hospital and the Mahusekwa China-Zimbabwe Friendship Hospital. Today, the partnership’s impact is measured not just in infrastructure and technology transfer, but in the thousands of lives saved, chronic pain relieved, and hope restored for Zimbabweans who had nowhere else to turn for care.

  • How Aussies taught kids to stay safe in the sun

    How Aussies taught kids to stay safe in the sun

    Skin cancer has long been one of the most pressing public health challenges for sun-drenched nations like Australia, where high ultraviolet radiation levels put residents at constant elevated risk. Four decades ago, public health officials made a pivotal decision to tackle this crisis from the ground up, focusing on the youngest generation to build lifelong safe sun habits. In 1981, they launched a revolutionary nationwide public education campaign that swapped dense clinical messaging for approachable, memorable pop culture-style content to teach children how to protect themselves from harmful sun exposure.

    The centerpiece of this innovative campaign was Sid the Seagull, a cheerful yellow cartoon character paired with an upbeat, catchy jingle that quickly embedded itself in the national consciousness. Unlike traditional public health announcements that relied on dry warnings and statistics, the campaign framed sun safety as a simple, everyday habit children could easily adopt. By leveraging a beloved cartoon mascot and an easily recallable tune, public health experts made core lessons about seeking shade, wearing protective clothing, and applying sunscreen stick with kids far more effectively than any textbook or lecture could.

    Decades later, this pioneering initiative is still held up as a global model for community-focused public health education. What began as a single national campaign to reduce rising skin cancer rates has reshaped how countries around the world approach sun safety outreach, proving that accessible, engaging messaging targeted at children can create generational shifts in health behavior.